Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. 1995

D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
Institute of Child Health, University of London, UK.

The pharmacokinetics of zidovudine (ZDV) and dideoxyinosine (ddI) were investigated following administration alone and in combination to children with symptomatic HIV disease. The children were studied on three separate occasions and received ZDV 200 mg m-2, ddI 100 mg m2 or a combination of ZDV 200 mg m-2 plus ddI 100 mg m-2. The administration of ddI did not significantly alter ZDV pharmacokinetics. The area under the curve (AUC) was 14.2 +/- 4.9 and 15.8 +/- 7.2 mumol l-1 h and elimination half-life (t1/2, z) was 1.4 +/- 0.4 and 1.2 +/- 0.2 h in the absence and presence of ddI respectively. The peak concentration (Cmax), time to peak (tmax) and apparent oral clearance (CL/F) were also unchanged. The administration of ZDV had no significant effect on ddI Cmax, tmax, t1/2,z, or CL/F, however the AUC was reduced by 19% (5.9 +/- 2.9 to 4.8 +/- 2.7 mumol l-1 h; P < 0.05). This study suggests that ZDV and ddI may be co-administered to children with symptomatic HIV disease without concern of a clinically relevant pharmacokinetic drug interaction.

UI MeSH Term Description Entries
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
May 1994, British journal of clinical pharmacology,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
October 1993, Annals of internal medicine,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
January 1993, Journal of acquired immune deficiency syndromes,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
July 1992, AIDS (London, England),
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
July 1990, The New England journal of medicine,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
March 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
August 2000, Pharmacotherapy,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
October 1989, American family physician,
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
March 1998, AIDS (London, England),
D Gibb, and M Barry, and S Ormesher, and L Nokes, and M Seefried, and C Giaquinto, and D Back
February 1994, Pharmaceutical research,
Copied contents to your clipboard!